Key Players
Competitive Landscape
Four supplier models compete in the complement inhibitors market: diversified biopharma groups, established rare-disease franchises, pathway-focused biotechnology companies and clinical-stage developers licensing selective upstream assets.
Portfolio investment has followed two routes since 2025: acquiring marketed complement franchises and improving delivery formats for treatment outside infusion centers. Biogen completed its Apellis acquisition in May 2026 following USD 689 million in 2025 revenue from the acquired products. UCB received a positive CHMP opinion for a Zilbrysq pre-filled pen in March 2026 that simplifies daily self-administration. Competition centers on approval breadth, dosing burden and infection-management support across approved indications within specialist treatment networks.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| In May 2026, Biogen completed its Apellis acquisition following USD 689 million in 2025 revenue from the acquired products. | Specialty centers favor portfolios that combine marketed C3 products with established reimbursement and medical-support teams across renal and retinal care. | Commercial complement franchises are consolidating under larger biopharma owners with broader launch and reimbursement capacity. | Renal and retinal complement products support portfolio expansion and specialist cross-coverage across shared treatment networks. |
| In March 2026, UCB received a positive CHMP opinion for the Zilbrysq pre-filled pen across Europe. | gMG patients and clinicians need simpler daily self-administration that reduces handling steps during continuing treatment. | Specialist competition increasingly includes device presentation alongside molecule choice and dosing frequency across home-administered therapies. | European device upgrades support continued Zilbrysq adoption among adults who need simpler daily self-administration devices. |
| In June 2026, Dianthus initiated the approximately 195-participant global Phase 3 EMERGE trial of claseprubart. | Neurology centers seek longer dosing intervals that reduce injection frequency without abandoning selective complement control. | Clinical competition is expanding upstream from C5 toward active C1s inhibition with longer dosing intervals. | Regional licensing and future gMG launches represent the clearest revenue routes for selective C1s inhibition across regulated markets. |
Five other competitors rely on approved portfolio breadth and pathway-specific evidence: AstraZeneca, Roche, Regeneron, Amgen and Omeros.
Source: Future Market Insights, Complement Inhibitors Market and Rare Disease Clinical Trials Market Reports, 2026-2036.
AstraZeneca and Novartis together cover terminal and proximal inhibition across intravenous and oral routes, while Biogen and UCB add subcutaneous or intravitreal formats.
Who leads the complement inhibitors market?
AstraZeneca PLC leads approved complement portfolio breadth through Soliris, Ultomiris and Voydeya across terminal pathway indications. Novartis AG competes through oral Fabhalta across PNH, C3G and primary IgA nephropathy in several regulated markets.
Which suppliers have documented regulatory approvals?
Regulatory approvals cover AstraZeneca and Novartis alongside Biogen-owned Apellis and Roche across blood, kidney and retinal indications. UCB and Regeneron contribute approved products across neuromuscular and metabolic disorders, with Amgen and Omeros adding treatments for vasculitis and transplant-related complications.
Which companies provide home-administered complement inhibitors?
Novartis supplies oral Fabhalta and UCB supplies once-daily subcutaneous Zilbrysq for eligible patients under specialist monitoring. Roche supplies monthly subcutaneous PiaSky following initial loading, and Biogen-owned Apellis supplies subcutaneous Empaveli for eligible PNH patients.
Which suppliers serve North America and Europe?
AstraZeneca and Novartis have verified commercial coverage across North America and Europe for several complement-mediated indications. Biogen-owned Apellis and Roche also serve both regions through C3 or C5 products using distinct administration routes. UCB adds once-daily subcutaneous C5 treatment through established commercial operations across Europe and North America.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| AstraZeneca PLC | Global commercial coverage | Alexion supplies Soliris and Ultomiris across several terminal complement indications, while oral Voydeya treats extravascular hemolysis as add-on therapy in PNH. |
| Novartis AG | Global commercial coverage | Fabhalta provides oral factor B inhibition across PNH, C3G and primary IgA nephropathy through one globally developed small-molecule platform. |
| Biogen Inc. / Apellis Pharmaceuticals, Inc. | United States with partner-led international coverage | Empaveli provides subcutaneous C3 inhibition across PNH and two rare kidney diseases, while Syfovre provides intravitreal treatment for geographic atrophy. |
| Roche Holding AG | Global commercial coverage | PiaSky provides monthly subcutaneous C5 inhibition for PNH following initial loading and supports trained self-administration for eligible patients in multiple regulated markets. |
| UCB S.A. | United States, Europe and Japan | Zilbrysq provides once-daily subcutaneous C5 inhibition for anti-AChR-positive generalized myasthenia gravis through self-administration by trained patients or caregivers. |
| Regeneron Pharmaceuticals, Inc. | United States with global clinical programs | Veopoz provides intravenous C5 inhibition for CHAPLE disease, while subcutaneous cemdisiran remains in late-stage development for generalized myasthenia gravis. |
| Amgen Inc. | United States commercial coverage | Tavneos remains available for severe active ANCA-associated vasculitis during the FDA withdrawal proceeding that began in April 2026. |
| Omeros Corporation | United States commercial coverage | Yartemlea provides intravenous MASP-2 inhibition for adult and pediatric TA-TMA patients across hospital and outpatient treatment settings in the United States. |
| Novo Nordisk | Global clinical development | Zaltenibart is a clinical-stage MASP-3 inhibitor that Novo Nordisk acquired from Omeros in December 2025 for continued global development. |
| Dianthus Therapeutics, Inc. | Global clinical development | Claseprubart provides investigational subcutaneous active C1s inhibition across neuromuscular Phase 2 and Phase 3 programs. |
Research Methodology
The companies in this section illustrate market structure and do not form a ranking of commercial leadership. Inclusion requires current evidence for an approved complement inhibitor or an active program that directly fits the defined market. Evidence comes from official approvals and company filings, plus transaction announcements and dated clinical disclosures tied to each named legal entity. Regulatory status remains product-specific, while the 46.0% C5 share represents an FMI market estimate for 2026.
